1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H1 2020, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.
Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 2, 13, 89, 72, 1, 5, 29 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 9, 5 and 3 molecules, respectively.
Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
- The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Myelodysplastic Syndrome - Overview
- Myelodysplastic Syndrome - Therapeutics Development
- Myelodysplastic Syndrome - Therapeutics Assessment
- Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
- Myelodysplastic Syndrome - Drug Profiles
- Myelodysplastic Syndrome - Dormant Projects
- Myelodysplastic Syndrome - Discontinued Products
- Myelodysplastic Syndrome - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Myelodysplastic Syndrome, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Myelodysplastic Syndrome - Pipeline by 4SC AG, H1 2020
- Myelodysplastic Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
- Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H1 2020
- Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H1 2020
- Myelodysplastic Syndrome - Pipeline by Acrotech Biopharma LLC, H1 2020
- Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
- Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H1 2020
- Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H1 2020
- Myelodysplastic Syndrome - Pipeline by AIMM Therapeutics BV, H1 2020
- Myelodysplastic Syndrome - Pipeline by ALX Oncology Inc, H1 2020
- Myelodysplastic Syndrome - Pipeline by Amphivena Therapeutics Inc, H1 2020
- Myelodysplastic Syndrome - Pipeline by Angiocrine Bioscience Inc, H1 2020
- Myelodysplastic Syndrome - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H1 2020
- Myelodysplastic Syndrome - Pipeline by Apogenix AG, H1 2020
- Myelodysplastic Syndrome - Pipeline by Aprea Therapeutics AB, H1 2020
- Myelodysplastic Syndrome - Pipeline by AptaBio Therapeutics Inc, H1 2020
- Myelodysplastic Syndrome - Pipeline by Aptevo Therapeutics Inc, H1 2020
- Myelodysplastic Syndrome - Pipeline by Aptose Biosciences Inc, H1 2020
- Myelodysplastic Syndrome - Pipeline by Y-Biologics Inc, H1 2020
- Myelodysplastic Syndrome - Pipeline by ZIOPHARM Oncology Inc, H1 2020
- Myelodysplastic Syndrome - Dormant Projects, H1 2020
- Myelodysplastic Syndrome - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Myelodysplastic Syndrome, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4SC AG
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AbbVie Inc
- Acceleron Pharma Inc
- Acrotech Biopharma LLC
- Actinium Pharmaceuticals Inc
- Aeglea BioTherapeutics Inc
- Agios Pharmaceuticals Inc
- AIMM Therapeutics BV
- ALX Oncology Inc
- Amphivena Therapeutics Inc
- Angiocrine Bioscience Inc
- Anhui Anke Biotechnology (Group) Co Ltd
- Apogenix AG
- Aprea Therapeutics AB
- AptaBio Therapeutics Inc
- Aptevo Therapeutics Inc
- Aptose Biosciences Inc
- Argenx SE
- Ascentage Pharma Group International
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- Aurigene Discovery Technologies Ltd
- Bayer AG
- Bellicum Pharmaceuticals Inc
- BerGenBio ASA
- Bio-Path Holdings Inc
- BioLineRx Ltd
- BioMed Valley Discoveries Inc
- BioTheryX Inc
- Boehringer Ingelheim International GmbH
- Boston Biomedical Inc
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- CellCentric Ltd
- Cellenkos Inc
- Cellerant Therapeutics Inc
- Celularity Inc
- Celyad Oncology
- CheckPoint Immunology Inc
- Chimerix Inc
- China NT Pharma Group Co Ltd
- Chordia Therapeutics Inc
- Cleave Therapeutics Inc
- Constellation Pharmaceuticals Inc
- CrystalGenomics Inc
- Cyclacel Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- DC Prime BV
- Deciphera Pharmaceuticals Inc
- Denovo Biopharma LLC
- DiNonA Inc
- Elixirgen Therapeutics LLC
- ExCellThera Inc
- Fate Therapeutics Inc
- Forma Therapeutics Inc
- Fujifilm Holdings Corp
- Gadeta BV
- Gamida Cell Ltd
- Geron Corp
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- GlycoMimetics Inc
- GT Biopharma Inc
- H3 Biomedicine Inc
- Harrow Health Inc
- Helocyte Biosciences Inc
- HemoGenyx LLC
- Hutchison MediPharma Ltd
- I-Mab Biopharma Co Ltd
- iCell Gene Therapeutics LLC
- IGF Oncology LLC
- Imago BioSciences Inc
- Immune System Key Ltd
- ImmunityBio Inc
- ImmunoGen Inc
- Incysus Therapeutics Inc
- Incyte Corp
- Inmune Bio Inc
- Io Therapeutics Inc
- Jasper Therapeutics Inc
- Jazz Pharmaceuticals Plc
- Johnson & Johnson
- Juno Therapeutics Inc
- Karyopharm Therapeutics Inc
- Keros Therapeutics Inc
- Kiadis Pharma NV
- Les Laboratoires Servier SAS
- Lixte Biotechnology Holdings Inc
- MacroGenics Inc
- Magenta Therapeutics Inc
- Mana Therapeutics Inc
- Marker Therapeutics Inc
- Mateon Therapeutics Inc
- MediGene AG
- Medivir AB
- MedPacto Inc
- MEI Pharma Inc
- Merck & Co Inc
- Merus NV
- Millennium Pharmaceuticals Inc
- Molecular Templates Inc
- Mustang Bio Inc
- Nanjing Legend Biotech Co Ltd
- NantKwest Inc
- Nemucore Medical Innovations Inc
- Newave Pharmaceutical Inc
- NexImmune Inc
- Nkarta Inc
- Nohla Therapeutics Inc
- Novartis AG
- Oncoceutics Inc
- Oncoheroes Biosciences Inc
- Onconova Therapeutics Inc
- Oncotelic Inc
- OncoTherapy Science Inc
- Ono Pharmaceutical Co Ltd
- Opsona Therapeutics Ltd
- Orca Biosystems Inc
- Orsenix Holdings BV
- Oxstem Ltd
- PersImmune Inc
- Pfizer Inc
- Pharma Mar SA
- Pinotbio Inc
- Plexxikon Inc
- Prelude Therapeutics Inc
- PRISM Pharma Co Ltd
- Rafael Pharmaceuticals Inc
- Ryvu Therapeutics SA
- Sanofi
- Seattle Genetics Inc
- Sensei Biotherapeutics Inc
- Shanghai Yingli Pharmaceutical Co Ltd
- Silence Therapeutics Plc
- Sino Biopharmaceutical Ltd
- SiNOPSEE Therapeutics Pte Ltd
- SpecificiT Pharma Inc
- Stelexis Therapeutics LLC
- Sumitomo Dainippon Pharma Co Ltd
- Surface Oncology Inc
- Syntrix Biosystems Inc
- Tacitus Therapeutics Inc
- Takara Bio Inc
- Teva Pharmaceutical Industries Ltd
- TheraPharm Deutschland GmbH
- Toko Pharmaceutical Industries Co Ltd
- Tolero Pharmaceuticals Inc
- TOT Biopharm Co Ltd
- Treadwell Therapeutics Inc
- Trethera Corp
- Trillium Therapeutics Inc
- Vyriad Inc
- Y-Biologics Inc
- ZIOPHARM Oncology Inc
